摘要: During the last decade, a systematic effort to develop pharmacological treatment for Alzheimer disease (AD) has resulted into three drugs being registered first time in USA and Europe this specific indication. All are cholinesterase inhibitors (ChEI). The major therapeutic effect of ChEI on AD patients is maintain cognitive function at constant level during 6 months one year period as compared placebo. Additional drug effects might be slowing deterioration improving behavioral daily living conditions. Comparison clinical demonstrates rather similar magnitude improvement measures. For some drugs, may represent an upper limit while other it still possible increase further benefit. In order maximize prolong positive important start early adjust dosage treatment. Recent studies show that many stabilization produced by can prolonged long 24 month period. explain stabilizing ChEI, mechanism than AChE inhibition, based beta-amyloid metabolism, postulated.
springer.com
sci-hub.se 参考文章(29)
Ravi Anand, Richard D. Hartman, Peggy E. Hayes, Marguirguis Gharabawi, An Overview of the Development of SDZ ENA 713, A Brain Selective Cholinesterase Inhibitor Birkhäuser Boston. pp. 239- 243 ,(1997) , 10.1007/978-1-4612-4116-4_35
Bruno P. Imbimbo, Paolo E. Lucchelli, A Pharmacodynamic Strategy to Optimize the Clinical Response to Eptastigmine (MF-201) Birkhäuser Boston. pp. 103- 107 ,(1994) , 10.1007/978-1-4615-8149-9_18
Ezio Giacobini, Cholinesterase Inhibitors Do More than Inhibit Cholinesterase Birkhäuser Boston. pp. 187- 204 ,(1997) , 10.1007/978-1-4612-4116-4_29
Robert E. Becker, Pamela Moriearty, Latha Unni, The Second Generation of Cholinesterase Inhibitors: Clinical and Pharmacological Effects Cholinergic Basis for Alzheimer Therapy. pp. 263- 296 ,(1991) , 10.1007/978-1-4899-6738-1_30
L. J. Thal, P. A. Fuld, D. M. Masur, N. S. Sharpless, Oral physostigmine and lecithin improve memory in Alzheimer disease. Annals of Neurology. ,vol. 13, pp. 491- 496 ,(1983) , 10.1002/ANA.410130504
T Mattio, M McIlhany, E Giacobini, M Hallak, The effects of physostigmine on acetylcholinesterase activity of CSF plasma and brain. A comparison of intravenous and intraventricular administration in beagle dogs. Neuropharmacology. ,vol. 25, pp. 1167- 1177 ,(1986) , 10.1016/0028-3908(86)90166-8
Richard Hartman, Yves Agid, Ravi Anand, Michael Rösler, Peter Dal-Bianco, Ana Cicin-Sain, Hannes B Stähelin, Marguirguis Gharabawi, Serge Gauthier, Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ. ,vol. 318, pp. 633- 640 ,(1999) , 10.1136/BMJ.318.7184.633
Martin Farlow, Stephen I Gracon, Linda A Hershey, Karen W Lewis, Carl H Sadowsky, Jann Dolan-Ureno, Stephen W Asher, Craig Beaver, Diane Hamilton, Scott M Bergman, Linda F Roger, Sandra E Black, Sandra Carr, Tamara Winchester, Elizabeth Layne, Christopher Clark, James Dexter, Eugene A DuBoff, Hugh Hendrie, Judy Caress, Rhonna Shatz, George R Hanna, H Robert Brashear, Paula Damgaard, Kerry Donnelly, Karen Burch, Richard W Homan, A John McSweeney, Mary Ann Barczak, Jeffrey A Mattes, Allison M Hermann, Erich Mohr, Tilak Mendis, Jeremy Roberts, Linda Begin, Margaret Sampson, Brian R Ott, Margaret C Lannon, J Joseph Prendergast, Sherna Madan, Roxann Hanning, Walter Martinez, Reed Stone, Paul Winner, Jose Zuniga, Laszlo J Mate, BJ Ehlert, Caria Lessard, Benjamin Seltzer, John R Taylor, VP Calabrese, SW Harkins, SJ Weis, Walter Slade, Barbara R Sommer, Melvin Wichter, Michael Schwartz, Joey Eastman, Stephen G Thein, Geri Williams, Judith A Dewar, Norman L Foster, Laurie A Bluemlein, Douglas J Gelb, Stanley Berent, Bruno Giordani, Beth A Baron, Sharie Myers, A Controlled Trial of Tacrine in Alzheimer's Disease JAMA: The Journal of the American Medical Association. ,vol. 268, pp. 2523- 2529 ,(1992) , 10.1001/JAMA.1992.03490180055026
Sharon L. Rogers, Lawrence T. Friedhoff, The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial Dementia. ,vol. 7, pp. 293- 303 ,(1996) , 10.1159/000106895
B.P Imbimbo, P Martelli, WM Troetel, F Lucchelli, U Lucca, LJ Thal, and The Eptastigmine Study Group, None, Efficacy and safety of eptastigmine for the treatment of patients with Alzheimer’s disease Neurology. ,vol. 52, pp. 700- 708 ,(1999) , 10.1212/WNL.52.4.700